Maravai Lifesciences Holdings (MRVI) risk factors
Item 1A of every Maravai Lifesciences Holdings, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors71 risks7 new8 dropped12 reworded
Maravai faces significant operational disruption following executive turnover and the 2025 Corporate Realignment Plan. Debt covenants, raw material inflation, and tax receivable agreement obligations threaten financial results. Restatements of quarterly financial statements highlight internal control and revenue recognition risks.
Filed Feb 26, 2026 - FY2024 10-K risk factors72 risks
Revenue heavily relies on high-volume sales of CleanCap, which have fluctuated significantly since 2022. The company faces ongoing customer demand unpredictability, product concentration risks, and intense industry competition. Substantial goodwill impairment charges highlight market and economic headwinds in nucleic acid production.
Filed Mar 18, 2025